[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (42)

Search Parameters:
Keywords = lymphoscintigraphy

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
13 pages, 1773 KiB  
Article
Sentinel Lymph Node Detection in Early-Stage Oral Squamous Cell Carcinoma Using Magnetic Resonance Lymphography: A Pilot Study
by Dominique N. V. Donders, Rutger Mahieu, Roosmarijn S. Tellman, Marielle E. P. Philippens, Robert J. J. van Es, Ellen M. Van Cann, Gerben E. Breimer, Remco de Bree and Bart de Keizer
J. Clin. Med. 2024, 13(23), 7052; https://doi.org/10.3390/jcm13237052 - 22 Nov 2024
Viewed by 476
Abstract
Objectives: To assess the efficacy of magnetic resonance (MR) lymphography with gadobutrol contrast for sentinel lymph node (SLN) mapping in early-stage oral squamous cell carcinoma (OSCC). Methods: This pilot study compared the identification of SLNs by MR lymphography using a gadolinium-based contrast agent [...] Read more.
Objectives: To assess the efficacy of magnetic resonance (MR) lymphography with gadobutrol contrast for sentinel lymph node (SLN) mapping in early-stage oral squamous cell carcinoma (OSCC). Methods: This pilot study compared the identification of SLNs by MR lymphography using a gadolinium-based contrast agent (gadobutrol) to conventional [99mTc]Tc-nanocolloid lymphoscintigraphy (including single-photon emission computed tomography/computed tomography (SPECT/CT)) in 10 early-stage OSCC patients undergoing SLN biopsy. The patients initially underwent conventional lymphoscintigraphy following the peritumoral administration of indocyanine green [99mTc]Tc-nanocolloid (120 megabecquerel; ~0.5 mL). Subsequently, 0.5–1.0 mL gadobutrol was peritumorally injected, and MR imaging was acquired for 30 min. The following day, the identified SLNs were harvested and subjected to a histopathological assessment. The MR lymphography and [99mTc]Tc-nanocolloid lymphoscintigraphy results were evaluated and compared with respect to those of the SLN identification. The reference standard consisted of a histopathological evaluation of the harvested SLNs, complementary neck dissection specimens, and follow-up data. Results: The MR lymphography detected 16 out of 27 SLNs identified by [99mTc]Tc-nanocolloid lymphoscintigraphy, revealing an additional SLN that did not harbor metastasis. MR lymphography failed to identify any SLNs in one patient. Of the seven histopathologically positive SLNs detected by [99mTc]Tc-nanocolloid lymphoscintigraphy, three were identified by MR lymphography. All patients remained disease-free after a median follow-up of 16 months. Compared to [99mTc]Tc-nanocolloid lymphoscintigraphy, MR lymphography using gadobutrol achieved an SLN identification rate of 59%, a sensitivity of 75%, and a negative predictive value of 86%. Conclusions: MR lymphography using gadobutrol demonstrates limited reliability for SLN mapping in early-stage OSCC. Full article
(This article belongs to the Section Oncology)
Show Figures

Figure 1

Figure 1
<p>Conventional [<sup>99m</sup>Tc]Tc-nanocolloid lymphoscintigraphy and gadobutrol-enhanced MR lymphography. (<b>A</b>) Conventional [<sup>99m</sup>Tc]Tc-nanocolloid lymphoscintigraphy of a patient diagnosed with cT1N0 OSCC on the right side of the oral tongue (patient 2; <a href="#jcm-13-07052-t002" class="html-table">Table 2</a>), sentinel lymph node in level Ib on the right side with uptake of [<sup>99m</sup>Tc]Tc-nanocolloid. (<b>B</b>) Gadobutrol-enhanced MR lymphography for the same patient depicting the sentinel lymph node in level Ib on the right side (red circle).</p>
Full article ">Figure 2
<p>Gadobutrol-enhanced MR lymphography with lymphatic vessel drainage. Gadobutrol-enhanced MR lymphography of a patient diagnosed with cT1N0 OSCC on the left side of the oral tongue (patient 9; <a href="#jcm-13-07052-t002" class="html-table">Table 2</a>) depicting the sentinel lymph node in level IIa on the left side (*) and lymphatic drainage with uptake of gadobutrol (red arrow).</p>
Full article ">Figure 3
<p>Dynamic MR lymphography. Contrast-enhanced dynamic MR images acquired for 10 min after peritumoral injection of undiluted gadobutrol in the same patient as <a href="#jcm-13-07052-f001" class="html-fig">Figure 1</a> (patient 2; <a href="#jcm-13-07052-t002" class="html-table">Table 2</a>). Rapid lymphatic drainage of gadobutrol was observed through dynamic MR lymphography, with gadobutrol washed out from the SLN within 7 min. (<b>A</b>) Initial dynamic MR depicting the sentinel lymph node in level Ib on the right side (red circle). (<b>B</b>) MR imaging acquired at 6 min and 23 s following (<b>A</b>), showing the same SLN in level Ib on the right side (red circle).</p>
Full article ">Figure 4
<p>MR lymphography with paramagnetic artifact due to [<sup>99m</sup>Tc]Tc-nanocolloid. Gadobutrol-enhanced MR lymphography in a patient diagnosed with cT1N0 OSCC on the right side of the oral tongue (patient 4), showing an artifact of [<sup>99m</sup>Tc]Tc-nanocolloid radiotracer at the injection site (*).</p>
Full article ">
3 pages, 2708 KiB  
Interesting Images
Unexplained Giant Genital Enlargement: Is It Due to Inverse Psoriasis?
by Francesco Natale and Giovanni Cimmino
Reports 2024, 7(4), 92; https://doi.org/10.3390/reports7040092 - 7 Nov 2024
Viewed by 543
Abstract
A healthy 54-year-old man previously presented to vascular surgeons with a 4-year history of swelling of the penis and scrotum was scheduled for ultrasound evaluation in the angiology office in our department. At presentation, there was a giant enlargement of the penis and [...] Read more.
A healthy 54-year-old man previously presented to vascular surgeons with a 4-year history of swelling of the penis and scrotum was scheduled for ultrasound evaluation in the angiology office in our department. At presentation, there was a giant enlargement of the penis and scrotum, without swelling of the legs. Ultrasound evaluation was negative for vascular abnormalities. A diagnosis of chronic lymphatic disease was suspected; thus, a lymphoscintigraphy was performed. This test was normal showing, a good visualization of major lymphatics. The patients had a history of psoriasis with a documented previous event of flexural psoriasis involving his genitals with secondary infection 4 years before. Since that infection, his genitals progressively increased in size, and despite medical treatment and different surgical evaluations, the patient’s symptoms have not resolved, with marked disability associated with walking and sexual activity. Full article
Show Figures

Figure 1

Figure 1
<p>A healthy 54-year-old man previously presented to vascular surgeons with a 4-year history of swelling of the penis and scrotum was scheduled for ultrasound evaluation in the angiology office. At presentation, there was a giant enlargement of the penis and scrotum, without swelling of the legs (<b>A</b>). The penile ultrasound was negative for vascular abnormalities and/or thrombotic complications (<b>B</b>). A diagnosis of chronic lymphatic disease was suspected; thus, a lymphoscintigraphy was performed (<b>C</b>). This test was normal, showing a good visualization of major lymphatics. The patient had a history of psoriasis, with a documented previous event of flexural psoriasis, as shown in (<b>D</b>) (axillary fossa) and (<b>E</b>) (left and right gluteus and intergluteal cleft), also involving his genitals with secondary infection 4 years before. Since that infection, his genitals progressively increased in size, and despite medical treatment and different surgical evaluation, the patient’s symptoms did not resolve, with marked disability related to walking and sexual activity. The diagnostic work-up for filariasis was performed as soon as the genital enlargement started, with negative results (direct detection in the blood, antigen detection and molecular diagnosis by PCR). The patient reported that, before experiencing penis enlargement, an acute phase of psoriasis occurred with signs of infection, as diagnosed by the family practitioner, and because of that, empirical antibiotic treatment was started. Taking into account the negative results of the test for filariasis, and the absence of vascular obstruction (as shown by the Doppler evaluation) as well as lymphatic obstruction (as shown by the lymphoscintigraphy), the role of inverse psoriasis in generating this process was postulated.</p>
Full article ">
11 pages, 4043 KiB  
Article
Characterizing Normal Upper Extremity Lymphatic Flow with 99mTc In-House Dextran: A Retrospective Study
by Wiroj Katiyarangsan, Putthiporn Charoenphun, Krisanat Chuamsaamarkkee, Suchawadee Musikarat, Kidakorn Kiranantawat, Chaninart Sakulpisuti, Kanungnij Thamnirat, Arpakorn Kositwattanarerk, Chanika Sritara and Wichana Chamroonrat
Diagnostics 2024, 14(17), 1960; https://doi.org/10.3390/diagnostics14171960 - 5 Sep 2024
Viewed by 1149
Abstract
Lymphoscintigraphy evaluates the lymphatic system using radiocolloid compounds like 99mTc-sulfur colloid and 99mTc-nanocolloid, which vary in particle size and distribution timing. A local in-house Dextran kit (15–40 nm) was developed in 2005 and began clinical use in 2008 to localize sentinel [...] Read more.
Lymphoscintigraphy evaluates the lymphatic system using radiocolloid compounds like 99mTc-sulfur colloid and 99mTc-nanocolloid, which vary in particle size and distribution timing. A local in-house Dextran kit (15–40 nm) was developed in 2005 and began clinical use in 2008 to localize sentinel lymph nodes; diagnose lymphedema; and detect lymphatic leakage. The normal drainage pattern remains unexplored. We retrospectively analyzed 84 upper extremity lymphoscintigraphies from 2008 to 2021. 99mTc in-house Dextran was intradermally injected into both hands, followed by whole-body imaging at specified intervals (≤15 min; 16–30 min; 31–45 min; 46–60 min), with some receiving delayed imaging. Visual and quantitative analyses recorded axillary and forearm lymph nodes and liver, kidney, and urinary bladder activity. Results showed 92% (77/84) upper extremity lymphatic tract visualization within 45 min. Axillary node detection rates increased from 46% (≤15 min) to 86% (46–60 min). Delayed imaging further revealed nodes. Epitrochlear or brachial node visualization was rare (4%, 3/84). Hepatic, renal, and urinary bladder activity was noted in 54%, 71%, and 93% at 1 h, respectively. The axillary node uptake ratio was minimal (<2.5% of injection site activity; median 0.33%). This study characterizes normal upper extremity lymphatic drainage using 99mTc in-house Dextran, offering insights into its clinical application Full article
(This article belongs to the Special Issue Research Update on Nuclear Medicine)
Show Figures

Figure 1

Figure 1
<p>Anterior images at four time-points during the upper extremity lymphoscintigraphy protocol, illustrating sampled regions of interest (ROIs) indicated by circles. The ROIs were positioned over the normal upper extremity injection site (right hand) and the ipsilateral axillary lymph node in the right upper extremity. Notably, both hands exhibit injection site activity. However, no forearm lymph nodes were detected throughout the study. The 15-min image initially displays a lymphatic draining tract (T) in the right upper extremity and two right axillary lymph nodes, accompanied by fainter activity in the liver (L), kidney (K), and urinary bladder (U). In addition, lymphedema scintigraphy findings of the left upper extremity are evidenced by chronic dermal backflow and absence of typical lymphatic tract and node visualization, attributable to previous resection of left breast cancer.</p>
Full article ">Figure 2
<p>The sequence of participant selection criteria for inclusion and exclusion.</p>
Full article ">Figure 3
<p>Anterior images of 3 patients (<b>A</b>–<b>C</b>) demonstrated variation of the normal upper extremity at the left side of patient A and the right side of patients B and C. Up to 5 axillary lymph nodes (large red circle) of patient A’s left upper extremity were counted, with clear visualization and increasing number over time. Forearm nodes were seen in patient C’s upper extremities at 4 h (arrows), one on each side. In patient B, organs, i.e., liver, kidneys, and urinary bladder, are hardly seen even up to 2 h. The findings of upper extremity lymphedema and chronic lymphatic obstruction post-MRM at the right side of patient A and the left side of patient B are as aforementioned in <a href="#diagnostics-14-01960-f001" class="html-fig">Figure 1</a>’s legend. Although clinical long-term left forearm edema of patient C and some radiotracers accumulate prolongedly in the medial aspect of the left forearm, there is no definite scintigraphy evidence of lymphatic obstruction of patient C’s left upper extremity.</p>
Full article ">
13 pages, 3975 KiB  
Article
Topography and Lateralization of Nodal Metastases in Muscle-Invasive Bladder Cancer Using Super-Extended Pelvic Lymph Node Dissection with the Sentinel Lymph Node Technique
by Adam Gurwin, Jakub Karwacki, Mateusz Dorochowicz, Kamil Kowalczyk, Łukasz Nowak, Diana Jędrzejuk, Wojciech Krajewski, Agnieszka Hałoń, Marek Bolanowski, Tomasz Szydełko and Bartosz Małkiewicz
J. Clin. Med. 2024, 13(17), 5127; https://doi.org/10.3390/jcm13175127 - 29 Aug 2024
Viewed by 918
Abstract
Background: This study assessed the topography and lateralization of lymph node (LN) metastases in muscle-invasive bladder cancer (MIBC) patients using super-extended pelvic lymph node dissection (sePLND) with sentinel lymph node dissection (SLND). Methods: We analyzed 54 MIBC patients who underwent cystectomy with sePLND [...] Read more.
Background: This study assessed the topography and lateralization of lymph node (LN) metastases in muscle-invasive bladder cancer (MIBC) patients using super-extended pelvic lymph node dissection (sePLND) with sentinel lymph node dissection (SLND). Methods: We analyzed 54 MIBC patients who underwent cystectomy with sePLND and SLND. Tumor location was classified using cystoscopy. Nanocolloid-Tc-99m was injected peritumorally. Preoperative SPECT/CT lymphoscintigraphy and an intraoperative gamma probe were used for SLN detection. Results: A total of 1414 LNs, including 192 SLNs, were resected from 54 patients. Metastases were found in 72 LNs from 22 patients (41%). The obturator fossa was the primary site for LN metastases (37.5%). SLNs were most common in the external iliac region (34.4%). In 36% of the patients with positive LNs, metastases were identified only through sePLND. In 9% of the patients, metastases were found solely in the pararectal region, identified through SLND. Tumor lateralization correlated with ipsilateral positive LNs, but 20% of the patients had contralateral metastases. Conclusions: The pararectal region may be the exclusive site for positive LNs in MIBC. The obturator fossa is the most prevalent region for LN metastases. Unilateral PLND should be avoided due to the risk of contralateral metastases. Combining sePLND with SLND improves staging. Full article
(This article belongs to the Section Nephrology & Urology)
Show Figures

Figure 1

Figure 1
<p>Patient selection and study design.</p>
Full article ">Figure 2
<p>The anatomical diagram of pelvic lymph node dissection (PLND) templates divided into regions: the obturator fossa (red), external iliac vessels (blue), internal iliac vessels (yellow), common iliac vessels (green), the presacral area (purple), and the Marcille’s fossa (gray; lying behind the plane). The limited PLND (lPLND) comprises the red region; standard PLND (sPLND) includes red and blue areas; extended PLND (ePLND) covers red, blue, and yellow regions; modified-extended PLND (mePLND) covers red, blue, yellow, and purple regions; super-extended PLND (sePLND) comprises all depicted lymph node areas.</p>
Full article ">Figure 3
<p>Methodology of LN mapping—presented in our previous paper [<a href="#B15-jcm-13-05127" class="html-bibr">15</a>]. (<b>A</b>) Sentinel lymph nodes (SLNs) localized using SPECT-CT images and mapped on the template (<b>B</b>); (<b>C</b>,<b>D</b>) lymphadenectomy specimens corresponding to specific anatomical areas.</p>
Full article ">Figure 4
<p>Depiction of (<b>A</b>) sentinel lymph node and (<b>B</b>) metastatic lymph node quantities. Color-coded schematics represent specific lymph node groups. Red: obturator; yellow: internal iliac; blue: external iliac; purple: presacral; green: common iliac; black: paraaortic; pink: paracaval; brown: pararectal.</p>
Full article ">
12 pages, 4363 KiB  
Article
A Multimodal Protocol Combining 99mTc-Tilmanocept with Indocyanine Green Fluorescence Lympho-Angiography for Sentinel Lymph Node Biopsy in Early-Stage Oral Cancer: A Case Series
by Andrea Galli, Carla Canevari, Emilio Salerno, Ayhan Irem, Marco Familiari, Carlo Pettirossi, Rosa Alessia Battista, Arturo Chiti, Mario Bussi and Leone Giordano
Diagnostics 2024, 14(16), 1805; https://doi.org/10.3390/diagnostics14161805 - 19 Aug 2024
Viewed by 830
Abstract
Sentinel lymph node biopsy (SLNB) is currently considered as a viable alternative to elective neck dissection (END) for the management of cN0 oral cavity squamous cell carcinoma (OCSCC). However, some difficulties were detected in sentinel lymph node (SLN) identification in floor of mouth [...] Read more.
Sentinel lymph node biopsy (SLNB) is currently considered as a viable alternative to elective neck dissection (END) for the management of cN0 oral cavity squamous cell carcinoma (OCSCC). However, some difficulties were detected in sentinel lymph node (SLN) identification in floor of mouth (FOM) and ventral tongue tumors because of the so-called “shine-through radioactivity” of the injection site, which may mask nodal hotspots in proximity. We assessed the feasibility and the potential strengths of combining 99mTc-Tilmanocept with indocyanine green (ICG) fluorescence lympho-angiography in a dedicated multimodal protocol for SLNB in T1/T2N0 oral cancer to evaluate the synergistic role of each of these two tracers in providing the appropriate sensitivity and ease of learning, even in such a critical anatomical subsite. A detailed, stepwise description of our multimodal protocol is provided, together with the presentation of its application in two cases of early-stage ventral tongue tumors. Radioactive guidance with 99mTc-Tilmanocept was used preoperatively to perform planar lymphoscintigraphy and single-photon emission computed tomography/computed tomography and to define the nodal hotspot(s) and the surgical “roadmap”. In addition, it was used intraoperatively to pinpoint the SLN location within each nodal hotspot with high specificity but limited spatial resolution. Optical guidance with ICG injection at the tumor bed and near-infrared fluorescence imaging was then added, providing intuitive intraoperative guidance within each nodal hotspot with high spatial resolution. Our small experience with this protocol is illustrated and future perspectives are highlighted. Full article
(This article belongs to the Special Issue Advances in Diagnosis and Treatment in Otolaryngology)
Show Figures

Figure 1

Figure 1
<p>(<b>A</b>) Preoperative <sup>99m</sup>Tc-Tilmanocept submucosal injections around the tumor at cardinal points (asterisks) in healthy mucosa. (<b>B</b>) Indocyanine green injection directly at the margins of the tumor bed with four peripheral injections immediately after transoral laser excision.</p>
Full article ">Figure 2
<p>(<b>A</b>,<b>B</b>) Preoperative SPECT/CT with identification of multiple nodal hotspots (lighter circular areas encircled by a purplish ring, or, for (2), the purplish region) at levels IB (2), IIA (1) and III (4) on the left side and at level III (3) on the right side; hotspot at the primary injection site was also visible (asterisk).</p>
Full article ">Figure 3
<p>(<b>A</b>,<b>B</b>) Intraoperative identification with infrared camera at level III on the right side of a “hot” and “fluorescent” sentinel lymph node (SLN; white arrow) beneath a parasentinel node (asterisk): (<b>C</b>,<b>D</b>) Fluorescence was evaluated point by point by software estimation of the relative indocyanine green (ICG) dye uptake of the putative SLN ((<b>C</b>), 101%) in comparison with adjacent lymphoid tissue ((<b>D</b>), 5%), defining a SLN-to-background ICG ratio; a percentage was provided in real time by moving the infrared camera all along the surgical field.</p>
Full article ">Figure 4
<p>(<b>A</b>) A moderately differentiated squamous cell carcinoma (SCC) was proven in the glossectomy specimen with a depth-of-infiltration of 3.5 mm (pT1) H&amp;E, magnification × 10. (<b>B</b>,<b>C</b>) A step serial sectioning protocol was applied for sentinel lymph node (SLN) histopathological analysis, founding a micrometastasis (diameter: 0.5 mm; black arrow, (<b>B</b>); highly magnified, H&amp;E, magnification × 3. (<b>C</b>) in the left IIA SLN, H&amp;E, magnification × 25.</p>
Full article ">Figure 5
<p>(<b>A</b>) Preoperative SPECT/CT with identification of two nodal hotspots (lighter circular areas encircled by a purplish ring) at levels IIA on the right side, one more cranially (<b>left</b>) and one more caudally (<b>right</b>). (<b>B</b>) Skin landmarking.</p>
Full article ">Figure 6
<p>Intraoperative view during dissection within the right level IIA hotspot highlighting the exposure of a para-SLN (asterisk, grasped with a forcep; (<b>A</b>,<b>B</b>)) and an SLN emerging from deep within it (circle; (<b>C</b>,<b>D</b>)), with optical guidance allowing proper discrimination between them. In particular, fluorescence imaging allows for better spatial resolution than radioactive guidance because of the dimensions of the portable gamma detection probe.</p>
Full article ">Figure 7
<p>Postoperative findings at a 6-month follow-up both on the neck side (<b>left</b>) and on the tongue side (<b>right</b>), with excellent aesthetic and functional outcome.</p>
Full article ">Figure 8
<p>A stepwise description of the proposed multimodal protocol for sentinel lymph node biopsy with double guidance. SPECT/CT: single-photon emission computed tomography/computed tomography; ICG: indocyanine green; SLN: sentinel lymph node.</p>
Full article ">
15 pages, 4059 KiB  
Systematic Review
Sentinel Lymph Node Detection in Cutaneous Melanoma Using Indocyanine Green-Based Near-Infrared Fluorescence Imaging: A Systematic Review and Meta-Analysis
by Marcus Wölffer, Rémy Liechti, Mihai Constantinescu, Ioana Lese and Cédric Zubler
Cancers 2024, 16(14), 2523; https://doi.org/10.3390/cancers16142523 - 12 Jul 2024
Viewed by 1051
Abstract
The standard of care approach to identify sentinel lymph nodes (SLNs) in clinically non-metastatic cutaneous melanoma patients is technetium (Tc)-based lymphoscintigraphy. This technique is associated with radiation exposure, a long intervention time, high costs, and limited availability. Indocyanine green (ICG)-based near-infrared fluorescence imaging [...] Read more.
The standard of care approach to identify sentinel lymph nodes (SLNs) in clinically non-metastatic cutaneous melanoma patients is technetium (Tc)-based lymphoscintigraphy. This technique is associated with radiation exposure, a long intervention time, high costs, and limited availability. Indocyanine green (ICG)-based near-infrared fluorescence imaging offers a potential alternative if proven to be of comparable diagnostic accuracy. While several clinical cohorts have compared these modalities, no systematic review exists that provides a quantitative analysis of their results. Hence, a systematic literature review was conducted in December 2023 considering clinical studies comparing the diagnostic accuracy of ICG and Tc for sentinel lymph node biopsy in cutaneous melanoma patients. Three hundred nineteen studies were identified and further screened in accordance with the PRISMA 2020 guidelines, resulting in seven studies being included in the final meta-analysis. Tc identified a significantly higher number of SLNs and metastatic SLNs in prospective studies only. However, in the overall meta-analysis of all included comparative studies, no significant differences were found regarding the identification of metastatic patients or the false negative rate (FNR). ICG may be a non-inferior alternative to Tc for intraoperative guidance in sentinel lymph node biopsy in cutaneous melanoma patients. Future randomized controlled trials are needed, especially regarding the preoperative, transcutaneous identification of the affected lymph node basin. Full article
(This article belongs to the Section Systematic Review or Meta-Analysis in Cancer Research)
Show Figures

Figure 1

Figure 1
<p>PRISMA 2020 flow diagram of the database search [<a href="#B10-cancers-16-02523" class="html-bibr">10</a>].</p>
Full article ">Figure 2
<p>Methodological quality of included studies using the Methodological Index for Non-Randomized Studies (MINORS). + = 2 points, adequately/total agreement; ? = 1 point, reported but inadequate/partial agreement; − = 0 points, not reported/no agreement [<a href="#B14-cancers-16-02523" class="html-bibr">14</a>,<a href="#B18-cancers-16-02523" class="html-bibr">18</a>,<a href="#B19-cancers-16-02523" class="html-bibr">19</a>,<a href="#B20-cancers-16-02523" class="html-bibr">20</a>,<a href="#B21-cancers-16-02523" class="html-bibr">21</a>,<a href="#B22-cancers-16-02523" class="html-bibr">22</a>,<a href="#B23-cancers-16-02523" class="html-bibr">23</a>,<a href="#B24-cancers-16-02523" class="html-bibr">24</a>].</p>
Full article ">Figure 3
<p>Forest plot depicting effect estimates regarding the total number of SLNs identified by Tc or ICG during SLNBs out of all SLNs sampled, stratified according to retrospective and prospective studies by odds ratio. Blue square: point estimate of the effect for a single study sized according to study weight, black line: confidence interval, diamond: subgroup or overall effect estimate [<a href="#B18-cancers-16-02523" class="html-bibr">18</a>,<a href="#B19-cancers-16-02523" class="html-bibr">19</a>,<a href="#B20-cancers-16-02523" class="html-bibr">20</a>,<a href="#B21-cancers-16-02523" class="html-bibr">21</a>,<a href="#B22-cancers-16-02523" class="html-bibr">22</a>,<a href="#B23-cancers-16-02523" class="html-bibr">23</a>,<a href="#B24-cancers-16-02523" class="html-bibr">24</a>].</p>
Full article ">Figure 4
<p>Forest plot depicting effect estimates regarding the number of metastatic SLNs identified by Tc or ICG out of all the SLNs identified by each method, stratified according to retrospective and prospective studies by odds ratio. Blue square: point estimate of the effect for a single study sized according to study weight, black line: confidence interval, diamond: subgroup or overall effect estimate [<a href="#B18-cancers-16-02523" class="html-bibr">18</a>,<a href="#B20-cancers-16-02523" class="html-bibr">20</a>,<a href="#B21-cancers-16-02523" class="html-bibr">21</a>,<a href="#B22-cancers-16-02523" class="html-bibr">22</a>,<a href="#B23-cancers-16-02523" class="html-bibr">23</a>,<a href="#B24-cancers-16-02523" class="html-bibr">24</a>].</p>
Full article ">Figure 5
<p>Forest plot depicting effect estimates regarding the number of metastatic SLNs identified by Tc or ICG relative to the total number of metastatic SLNs, stratified according to retrospective and prospective studies with odds ratio. Blue square: point estimate of the effect for a single study sized according to study weight, black line: confidence interval, diamond: subgroup or overall effect estimate [<a href="#B18-cancers-16-02523" class="html-bibr">18</a>,<a href="#B20-cancers-16-02523" class="html-bibr">20</a>,<a href="#B21-cancers-16-02523" class="html-bibr">21</a>,<a href="#B22-cancers-16-02523" class="html-bibr">22</a>,<a href="#B23-cancers-16-02523" class="html-bibr">23</a>,<a href="#B24-cancers-16-02523" class="html-bibr">24</a>].</p>
Full article ">Figure 6
<p>Forest plot depicting effect estimates regarding the number of metastatic patients identified by Tc or ICG out of the total number of metastatic patients, stratified according to retrospective and prospective studies by odds ratio. Blue square: point estimate of the effect for a single study sized according to study weight, black line: confidence interval, diamond: subgroup or overall effect estimate [<a href="#B18-cancers-16-02523" class="html-bibr">18</a>,<a href="#B20-cancers-16-02523" class="html-bibr">20</a>,<a href="#B21-cancers-16-02523" class="html-bibr">21</a>,<a href="#B22-cancers-16-02523" class="html-bibr">22</a>,<a href="#B23-cancers-16-02523" class="html-bibr">23</a>,<a href="#B24-cancers-16-02523" class="html-bibr">24</a>].</p>
Full article ">Figure 7
<p>Forest plot depicting effect estimates regarding the number of false-negative patients missed by Tc or ICG out of the total number of true-positive and false-negative patients with corresponding risk differences. Blue square: point estimate of the effect for a single study sized according to study weight, black line: confidence interval, diamond: overall effect estimate [<a href="#B18-cancers-16-02523" class="html-bibr">18</a>,<a href="#B20-cancers-16-02523" class="html-bibr">20</a>,<a href="#B21-cancers-16-02523" class="html-bibr">21</a>,<a href="#B22-cancers-16-02523" class="html-bibr">22</a>].</p>
Full article ">
16 pages, 993 KiB  
Review
The Use of Sentinel Lymph Node Mapping for Canine Mast Cell Tumors
by Marta Romańska, Beata Degórska and Katarzyna A. Zabielska-Koczywąs
Animals 2024, 14(7), 1089; https://doi.org/10.3390/ani14071089 - 3 Apr 2024
Cited by 1 | Viewed by 3209
Abstract
Cancer is the leading cause of death in companion animals. The evaluation of locoregional lymph nodes, known as lymph node mapping, is a critical process in assessing the stage of various solid tumors, such as mast cell tumors (MCTs), anal gland anal sac [...] Read more.
Cancer is the leading cause of death in companion animals. The evaluation of locoregional lymph nodes, known as lymph node mapping, is a critical process in assessing the stage of various solid tumors, such as mast cell tumors (MCTs), anal gland anal sac adenocarcinoma, melanoma, and mammary gland adenocarcinoma. MCTs are among the most prevalent skin malignancies in dogs. Staging is used to describe the extent of neoplastic disease, provide a framework for rational treatment planning, and evaluate treatment results. The aim of this review is to present the current knowledge on sentinel lymph node (SLN) mapping in canine MCTs, its influence on treatment decisions and prognosis, as well as the advantages and limitations of different SLN techniques currently available in veterinary oncology. A search methodology was adopted using the PubMed, Scopus, and Google Scholar databases. Critical analyses of up-to-date research have shown that lymphoscintigraphy can achieve a lymph node detection rate of between 91 and 100%. This method is becoming increasingly recognized as the gold standard in both human and veterinary medicine. In addition, initial studies on a limited number of animals have shown that computed tomographic lymphography (CTL) is highly effective in the SLN mapping of MCTs, with detection rates between 90 and 100%. The first study on contrast-enhanced ultrasound (CEUS) also revealed that this advanced technique has up to a 95% detection rate in canine MCTs. These methods provide non-ionizing alternatives with high detection capabilities. Furthermore, combining computed tomography and near-infrared fluorescence (NIR/NIR-LND) lymphography is promising as each technique identifies different SLNs. Indirect lymphography with Lipiodol or Iohexol is technically feasible and may be also used to effectively detect SLNs. The integration of these mapping techniques into routine MCT staging is essential for enhancing the precision of MCT staging and potentially improving therapeutic outcomes. However, further clinical trials involving a larger number of animals are necessary to refine these procedures and fully evaluate the clinical benefits of each technique. Full article
Show Figures

Figure 1

Figure 1
<p>Radiographs presenting indirect lymphography 24 h after the peritumoral injection of Lipiodol in a dog with a tumor located in the popliteal region. (<b>a</b>) Lateral radiograph of the caudal part of the abdominal wall and popliteal region. A shadow in the popliteal region corresponds to the site of the injection of the contrast agent. The arrow indicates a superficial inguinal lymph node. (<b>b</b>) A radiograph that better visualizes the superficial inguinal sentinel lymph node (arrow).</p>
Full article ">Figure 2
<p>Intraoperative view of the ventral aspect of a neck after a four-quadrant injection of methylene blue into the tumor area; the tumor is located on the upper lip. The blue dye flows along with the lymph from the tumor masses to the SLN and the mandibular lymph node, staining it blue (arrow). This allows for the easier identification, dissection, and removal of the SLN.</p>
Full article ">
11 pages, 501 KiB  
Article
Sentinel Lymph Node Biopsy (SLNB) for Early-Stage Head and Neck Squamous-Cell Carcinoma of the Tongue: Twenty Years of Experience at I.N.T. “G.Pascale”
by Franco Ionna, Ettore Pavone, Corrado Aversa, Francesco Maffia, Raffaele Spinelli, Emanuele Carraturo, Giovanni Salzano, Fabio Maglitto, Marco Sarcinella, Roberta Fusco, Vincenza Granata, Secondo Lastoria, Francesco Del Prato and Maria Grazia Maglione
Cancers 2024, 16(6), 1153; https://doi.org/10.3390/cancers16061153 - 14 Mar 2024
Cited by 3 | Viewed by 2447 | Correction
Abstract
Oral tongue squamous-cell carcinoma (OTSCC) is the most prevalent malignancy in the head and neck region. Lymphatic spread, particularly to cervical lymph nodes, significantly impacts 5-year survival rates, emphasizing the criticality of precise staging. Metastatic cervical lymph nodes can decrease survival rates by [...] Read more.
Oral tongue squamous-cell carcinoma (OTSCC) is the most prevalent malignancy in the head and neck region. Lymphatic spread, particularly to cervical lymph nodes, significantly impacts 5-year survival rates, emphasizing the criticality of precise staging. Metastatic cervical lymph nodes can decrease survival rates by 50%. Yet, elective neck dissection (END) in T1–2 cN0 patients proves to be an overtreatment in around 80% of cases. To address this, sentinel lymph node biopsy (SLNB) was introduced, aiming to minimize postoperative morbidity. This study, conducted at the ENT and Maxillofacial Surgery department of the Istituto Nazionale Tumori in Naples, explores SLNB’s efficacy in early-stage oral tongue squamous-cell carcinoma (OTSCC). From January 2020 to January 2022, 122 T1/T2 cN0 HNSCC patients were enrolled. Radioactive tracers and lymphoscintigraphy identified sentinel lymph nodes, aided by a gamma probe during surgery. Results revealed 24.6% SLN biopsy positivity, with 169 SLNs resected and a 21.9% positivity ratio. The study suggests SLNB’s reliability for T1-2 cN0 OTSCC patient staging and early micrometastasis detection. Full article
(This article belongs to the Special Issue Modern Approach to Oral Cancer)
Show Figures

Figure 1

Figure 1
<p>Overall survival rate of patients with positive (red line) and negative SNL (blue line).</p>
Full article ">
15 pages, 2419 KiB  
Review
The Role of Imaging of Lymphatic System to Prevent Cancer Related Lymphedema
by Vincenzo Cuccurullo, Marco Rapa, Barbara Catalfamo, Gianluca Gatta, Graziella Di Grezia and Giuseppe Lucio Cascini
Bioengineering 2023, 10(12), 1407; https://doi.org/10.3390/bioengineering10121407 - 10 Dec 2023
Cited by 2 | Viewed by 1711
Abstract
Lymphedema is a progressive chronic condition affecting approximately 250 million people worldwide, a number that is currently underestimated. In Western countries, the most common form of lymphedema of the extremities is cancer-related and less radical surgical intervention is the main option to prevent [...] Read more.
Lymphedema is a progressive chronic condition affecting approximately 250 million people worldwide, a number that is currently underestimated. In Western countries, the most common form of lymphedema of the extremities is cancer-related and less radical surgical intervention is the main option to prevent it. Standardized protocols in the areas of diagnosis, staging and treatment are strongly required to address this issue. The aim of this study is to review the main diagnostic methods, comparing new emerging procedures to lymphoscintigraphy, considered as the golden standard to date. The roles of Magnetic Resonance Lymphangiography (MRL) or indocyanine green ICG lymphography are particularly reviewed in order to evaluate diagnostic accuracy, potential associations with lymphoscintigraphy, and future directions guided by AI protocols. The use of imaging to treat lymphedema has benefited from new techniques in the area of lymphatic vessels anatomy; these perspectives have become of value in many clinical scenarios to prevent cancer-related lymphedema. Full article
Show Figures

Figure 1

Figure 1
<p>Normal lymphoscintigraphy of upper limbs performed after injection under the deep aponeurosis of the first interdigital spaces of hands bilaterally, and subsequently after a subdermal injection of the second, third and fourth interdigital spaces with <sup>99m</sup>Tc albumin nanocolloid.</p>
Full article ">Figure 2
<p>Normal lymphoscintigraphy of the lower limbs performed after the injection under the deep aponeurosis of the third finger of feet bilaterally, and subsequently after a subdermal injection of the second, third and fourth interdigital spaces with <sup>99m</sup>Tc albumin nanocolloid.</p>
Full article ">
17 pages, 7774 KiB  
Review
Imaging Modalities for Evaluating Lymphedema
by Bendeguz Istvan Nagy, Balazs Mohos and Chieh-Han John Tzou
Medicina 2023, 59(11), 2016; https://doi.org/10.3390/medicina59112016 - 16 Nov 2023
Cited by 7 | Viewed by 2335
Abstract
Lymphedema is a progressive condition. Its therapy aims to reduce edema, prevent its progression, and provide psychosocial aid. Nonsurgical treatment in advanced stages is mostly insufficient. Therefore—in many cases—surgical procedures, such as to restore lymph flow or excise lymphedema tissues, are the only [...] Read more.
Lymphedema is a progressive condition. Its therapy aims to reduce edema, prevent its progression, and provide psychosocial aid. Nonsurgical treatment in advanced stages is mostly insufficient. Therefore—in many cases—surgical procedures, such as to restore lymph flow or excise lymphedema tissues, are the only ways to improve patients’ quality of life. Imaging modalities: Lymphoscintigraphy (LS), near-infrared fluorescent (NIRF) imaging—also termed indocyanine green (ICG) lymphography (ICG-L)—ultrasonography (US), magnetic resonance lymphangiography (MRL), computed tomography (CT), photoacoustic imaging (PAI), and optical coherence tomography (OCT) are standardized techniques, which can be utilized in lymphedema diagnosis, staging, treatment, and follow-up. Conclusions: The combined use of these imaging modalities and self-assessment questionnaires deliver objective parameters for choosing the most suitable surgical therapy and achieving the best possible postoperative outcome. Full article
(This article belongs to the Special Issue Imaging Technology of the Lymphatic System)
Show Figures

Figure 1

Figure 1
<p>Ultra-high-frequency ultrasound (48 MHz probe) accurately reveals lymphatic vessels and neighboring veins. The green arrow indicates the lymphatic collector; the blue arrow shows the vein.</p>
Full article ">Figure 2
<p>Lymphoscintigraphy (LS) reveals the lymphatic flow insufficiency. (<b>A</b>) Anteroposterior (AP) transmission LS scan shows the early distribution of the tracer; proximal lymph nodes can be observed. (<b>B</b>) Posteroanterior (PA) scan, early distribution. (<b>C</b>) AP LS scan demonstrates the late distribution of the isotope, showing lymphatic retention on the medial calf on the right side. (<b>D</b>) PA scan, late distribution.</p>
Full article ">Figure 3
<p>Taiwan Lymphoscintigraphy Staging differentiates lymphedema into 3 patterns and 7 stages: L0, normal drainage; P1–3, partial obstruction; T4–6, total obstruction. Cited with permission [<a href="#B41-medicina-59-02016" class="html-bibr">41</a>].</p>
Full article ">Figure 4
<p>(<b>A</b>) Lymphovenous anastomosis (LVA). An ecstatic lymphatic vessel (left side) is anastomosed to a reflux-free vein (right side). Wash-out of blood can be observed from the distal part of the vein to the patent venous valve. (<b>B</b>) Microscope-integrated intraoperative ICG-L ensures the patency of lympho-venosus anastomosis.</p>
Full article ">Figure 5
<p>Presentation of indocyanine green (ICG) lymphography on a specific lymphatic vessel, which is for lymphovenous anastomosis operation. (<b>A</b>) ICG lymphography markings on the skin (the green arrow indicates the lymphatic vessel, the blue arrow shows at the vein). Linear and dermal backflow (DB) patterns are indicated differently. (<b>B</b>) ICG lymphography patterns on the same region. (<b>C</b>) The previously detected lymphatic collector is dissected and verified under microscope. (<b>D</b>) Microscope-integrated ICG lymphography shows the functional lymphatic vessel. (<b>E</b>) The anastomosis is made with 11-0 non-absorbable monofil sutures. (<b>F</b>) Microscope-integrated ICG lymphography ensures the patency of the anastomosis and excludes any leakage. Lymphatic flow washes out blood from the vein.</p>
Full article ">Figure 6
<p>MRL of a patient with lower limb primary lymphedema. Hyperplasic lymphatic vessels and inguinal lymph nodes (arrow) of the right lower extremity are visible [<a href="#B55-medicina-59-02016" class="html-bibr">55</a>].</p>
Full article ">Figure 7
<p>The medial view of the right lower extremity of a woman in her thirties without any past medical history registered with photoacoustic/optoacoustic lymphangiography. (<b>A</b>) Both venules and lymphatic vessels are shown. (<b>B</b>) Only lymphatic vessels are shown. Cited with permission. [<a href="#B65-medicina-59-02016" class="html-bibr">65</a>].</p>
Full article ">Figure 8
<p>Lymphatic vessel photographed (<b>A</b>), the green square in A shows the area imaged with a microscope-integrated NIRF camera (<b>B</b>) and the green line in B indicates the position of the crossectional image captured with a microscope-integrated OCT (<b>C</b>). The diameter and wall-thickness of vessels can be measured precisely on the OCT images [<a href="#B70-medicina-59-02016" class="html-bibr">70</a>].</p>
Full article ">
17 pages, 544 KiB  
Review
The Role of Sentinel Lymph Node Biopsy in Breast Cancer Patients Who Become Clinically Node-Negative Following Neo-Adjuvant Chemotherapy: A Literature Review
by Giulia Ferrarazzo, Alberto Nieri, Emma Firpo, Andrea Rattaro, Alessandro Mignone, Flavio Guasone, Augusto Manzara, Giuseppe Perniciaro and Stefano Spinaci
Curr. Oncol. 2023, 30(10), 8703-8719; https://doi.org/10.3390/curroncol30100630 - 25 Sep 2023
Cited by 6 | Viewed by 4245
Abstract
Background: In clinically node-positive (cN+) breast cancer (BC) patients who become clinically node-negative (cN0) following neoadjuvant chemotherapy (NACT), sentinel lymph node biopsy (SLNB) after lymphatic mapping with lymphoscintigraphy is not widely accepted; therefore, it has become a topic of international debate. Objective: Our [...] Read more.
Background: In clinically node-positive (cN+) breast cancer (BC) patients who become clinically node-negative (cN0) following neoadjuvant chemotherapy (NACT), sentinel lymph node biopsy (SLNB) after lymphatic mapping with lymphoscintigraphy is not widely accepted; therefore, it has become a topic of international debate. Objective: Our literature review aims to evaluate the current use of this surgical practice in a clinical setting and focuses on several studies published in the last six years which have contributed to the assessment of the feasibility and accuracy of this practice, highlighting its importance and oncological safety. We have considered the advantages and disadvantages of this technique compared to other suggested methods and strategies. We also evaluated the role of local irradiation therapy after SLNB and state-of-the-art SLN mapping in patients subjected to NACT. Methods: A comprehensive search of PubMed and Cochrane was conducted. All studies published in English from 2018 to August 2023 were evaluated. Results: Breast units are moving towards a de-escalation of axillary surgery, even in the NACT setting. The effects of these procedures on local irradiation are not very clear. Several studies have evaluated the oncological outcome of SLNB procedures. However, none of the alternative techniques proposed to lower the false negative rate (FNR) of SLNB are significant in terms of prognosis. Conclusions: Based on these results, we can state that lymphatic mapping with SLNB in cN+ BC patients who become clinically node-negative (ycN0) following NACT is a safe procedure, with a good prognosis and low axillary failure rates. Full article
(This article belongs to the Collection New Insights into Breast Cancer Diagnosis and Treatment)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Flow of records searched according to the present systematic review.</p>
Full article ">
19 pages, 4263 KiB  
Article
Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Axillary Conversion after Neoadjuvant Chemotherapy—A Single-Tertiary Centre Experience and Review of the Literature
by Alexandra Maria Lazar, Mario-Demian Mutuleanu, Paula Monica Spiridon, Cristian Ioan Bordea, Tatiana Lucia Suta, Alexandru Blidaru and Mirela Gherghe
Diagnostics 2023, 13(18), 3000; https://doi.org/10.3390/diagnostics13183000 - 20 Sep 2023
Cited by 3 | Viewed by 2134
Abstract
(1) Introduction: Sentinel lymph node biopsy (SLNB) is widely used in breast cancer patients who undergo neoadjuvant chemotherapy (NAC), replacing axillary lymph node dissection. While commonly accepted for cN0 patients, its role in cN1/2 patients remains controversial. Our study aims to investigate the [...] Read more.
(1) Introduction: Sentinel lymph node biopsy (SLNB) is widely used in breast cancer patients who undergo neoadjuvant chemotherapy (NAC), replacing axillary lymph node dissection. While commonly accepted for cN0 patients, its role in cN1/2 patients remains controversial. Our study aims to investigate the role of SLNB in BC patients who underwent prior NAC and compare our results to those of other studies presented in the literature. (2) Materials and methods: Our retrospective study included 102 breast cancer patients who received NAC before 99mTc-albumin Nanocolloid SLN mapping and SLNB was performed, completed or not with axillary dissection. A review based on the PRISMA statement was also carried out, encompassing 20 studies. (3) Results: The lymphoscintigraphy performed after the administration of NAC presented an identification rate (IR) of 93.13%. IR for SLNB was 94.11%, with a false-negative rate (FNR) of 7.4%. After a median follow-up of 31.3 months, we obtained a distant disease-free survival rate of 98%. The results obtained by other groups were similar to those of our study, presenting IR in the range 80.8–96.8%, with FNR varying from 0 to 22%. (4) Conclusions: on conclusion, SLNB can accurately determine the lymph node status, with an acceptable FNR and maintain its expected prognostic role with low recurrence rates, and our results are comparable to those obtained by other studies. Full article
Show Figures

Figure 1

Figure 1
<p>Schematic representation of the process of literature selection for the qualitative review according to the PRISMA statement.</p>
Full article ">Figure 2
<p>Planar lymphoscintigraphy of 48-year-old patient diagnosed with Stage III invasive ductal carcinoma of breast, showing one left axillary sentinel lymph node (red arrow). Blue arrow represents injection site.</p>
Full article ">Figure 3
<p>Female patient aged 45 years old diagnosed with Stage II invasive ductal carcinoma of the breast. (<b>A</b>) Planar lymphoscintigraphy showed multiple SLNs (red arrows) localised in different lymph node levels and overlapping the injection site (blue arrow). (<b>B</b>) For more precise localisation of the SLNs, the patients underwent SPECT/CT examination that revealed lymphatic drainage originating from the peritumoural region into the right axillary region (involving 1 SLN) and the bilateral internal mammary regions (involving two nodes on the right side and one on the left side). Figure (<b>C</b>) shows a 3D rendering of the SLNs positions.</p>
Full article ">
15 pages, 297 KiB  
Review
Role of Nuclear Sentinel Lymph Node Mapping Compared to New Alternative Imaging Methods
by Vincenzo Cuccurullo, Marco Rapa, Barbara Catalfamo and Giuseppe Lucio Cascini
J. Pers. Med. 2023, 13(8), 1219; https://doi.org/10.3390/jpm13081219 - 31 Jul 2023
Cited by 3 | Viewed by 1679
Abstract
With the emergence of sentinel node technology, many patients can be staged histopathologically using lymphatic mapping and selective lymphadenectomy. Structural imaging by using US, CT and MR permits precise measurement of lymph node volume, which is strongly associated with neoplastic involvement. Sentinel lymph [...] Read more.
With the emergence of sentinel node technology, many patients can be staged histopathologically using lymphatic mapping and selective lymphadenectomy. Structural imaging by using US, CT and MR permits precise measurement of lymph node volume, which is strongly associated with neoplastic involvement. Sentinel lymph node detection has been an ideal field of application for nuclear medicine because anatomical data fails to represent the close connections between the lymphatic system and regional lymph nodes, or, more specifically, to identify the first draining lymph node. Hybrid imaging has demonstrated higher accuracy than standard imaging in SLN visualization on images, but it did not change in terms of surgical detection. New alternatives without ionizing radiations are emerging now from “non-radiological” fields, such as ophthalmology and dermatology, where fluorescence or opto-acoustic imaging, for example, are widely used. In this paper, we will analyze the advantages and limits of the main innovative methods in sentinel lymph node detection, including innovations in lymphoscintigraphy techniques that persist as the gold standard to date. Full article
14 pages, 673 KiB  
Article
Evaluation of Surgical Aid of Methylene Blue in Addition to Intraoperative Gamma Probe for Sentinel Lymph Node Extirpation in 116 Canine Mast Cell Tumors (2017–2022)
by Elisa Maria Gariboldi, Alessandra Ubiali, Lavinia Elena Chiti, Roberta Ferrari, Donatella De Zani, Davide Danilo Zani, Valeria Grieco, Chiara Giudice, Camilla Recordati, Damiano Stefanello and Luigi Auletta
Animals 2023, 13(11), 1854; https://doi.org/10.3390/ani13111854 - 2 Jun 2023
Cited by 3 | Viewed by 2132
Abstract
Methylene Blue (MB) is combined with radiopharmaceutical for intraoperative sentinel lymph node (SLN) mapping, but its role during SLN extirpation has not been investigated yet in veterinary medicine. The aim of this study was to assess whether MB increased surgical detection of SLN [...] Read more.
Methylene Blue (MB) is combined with radiopharmaceutical for intraoperative sentinel lymph node (SLN) mapping, but its role during SLN extirpation has not been investigated yet in veterinary medicine. The aim of this study was to assess whether MB increased surgical detection of SLN beyond the use of intraoperative gamma-probe (IGP) alone in clinically node-negative dogs with mast cell tumors (MCTs) following the detection of sentinel lymphocentrums (SLCs) via preoperative planar lymphoscintigraphy. Dogs enrolled underwent MCT excision and SLC exploration guided by both MB and IGP. Data recorded for each SLN were staining (blue/non-blue), radioactivity (hot/non-hot), and histopathological status (HN0-1 vs. HN2-3). A total of 103 dogs bearing 80 cutaneous, 35 subcutaneous, and 1 mucocutaneous MCTs were included; 140 SLCs were explored, for a total of 196 SLNs removed. Associating MB with IGP raised the SLNs detection rate from 90% to 95%. A total of 44% of SLNs were metastatic: 86% were blue/hot, 7% were only blue, 5% were only hot, and 2% were non-blue/non-hot. All HN3 SLNs were hot. Combining MB with IGP can increase the rate of SLN detection in dogs with MCTs; nonetheless, all lymph nodes identified during dissection should be removed, as they might be unstained but metastatic. Full article
(This article belongs to the Special Issue Recent Advances in the Treatment of Cancer in Domesticated Animals)
Show Figures

Figure 1

Figure 1
<p>Intraoperative scenario of SLC exploration using IGP with at least one “hot and blue” (C) or “hot and non-blue” (D) SLN deeper than “non-hot” SLNs (A and B). The surgeon removes all lymph nodes encountered during sentinel lymphocentrum exploration (both “non-hot” and “blue”, or “non-hot” and “non-blue”) until RC will be less than 10% of the hottest SLN extirped and no other lymph nodes are visible/palpable.</p>
Full article ">Figure 2
<p>Intraoperative scenario of SLC exploration using IGP, with at least one “hot and blue” (C) or “hot and non-blue” (D) SLN less deep than other non-hot SLNs (A and B). The surgeon removes the “hot” lymph nodes encountered during sentinel lymphocentrum exploration and all other lymph nodes identified using palpation or because they are very close (A) or visible (B) to hot nodes (C,D). The surgeon evaluates the field RC at the end of the surgical exploration. The exploration is stopped when the RC is less than 10% of the hottest SLN extirped and no other lymph nodes are visible/palpable.</p>
Full article ">
9 pages, 805 KiB  
Article
Lymphoscintigraphy versus Indocyanine Green Lymphography—Which Should Be the Gold Standard for Lymphedema Imaging?
by Brian A. Figueroa, Jacob D. Lammers, Mazen Al-Malak, Sonia Pandey and Wei F. Chen
Lymphatics 2023, 1(1), 25-33; https://doi.org/10.3390/lymphatics1010004 - 5 May 2023
Viewed by 4700
Abstract
Early detection and treatment can slow the progression of lymphedema. To diagnose lymphedema in the subclinical phase, a sensitive imaging modality is required. Radioisotope-based lymphoscintigraphy (LSG) has been the “gold standard” for a century. Indocyanine green lymphography (ICGL) is being used at our [...] Read more.
Early detection and treatment can slow the progression of lymphedema. To diagnose lymphedema in the subclinical phase, a sensitive imaging modality is required. Radioisotope-based lymphoscintigraphy (LSG) has been the “gold standard” for a century. Indocyanine green lymphography (ICGL) is being used at our institute for diagnosing and grading all lymphedema patients. In this study, ICGL disease detection rate was compared to that of LSG. Chart review of all patients who presented for lymphedema consult between February 2020 and April 2022 was conducted. Patients who underwent both LSG and ICG for extremity edema in symptomatic/asymptomatic limbs were included. A total of 50 limbs in 23 patients met the inclusion criteria. Of those, 37 were symptomatic and 13 were asymptomatic. LSG detected lymphatic dysfunction in 26/37(70%) of the symptomatic limbs while ICG detected the same in 37/37(100%) limbs (p < 0.01). In the asymptomatic group, LSG detected the disease in 1/13(8%) limbs while ICG detected lymphatic dysfunction in 8/13 (62%) limbs (p < 0.01). LSG missed symptomatic limbs 30% of the time, whereas ICG did not miss any symptomatic limbs (p < 0.01). LSG missed asymptomatic disease 54% of the time (p < 0.01) compared to ICG. In conclusion, ICG lymphography was determined to have a higher lymphatic dysfunction detection rate compared to LSG. Full article
Show Figures

Figure 1

Figure 1
<p>(<bold>A</bold>) Lymphoscintigram of the lower limbs in a patient with lymphedema showing channels, tortuosity of channels and dermal backflow. (<bold>B</bold>) Lower extremity indocyanine green lymphography showing a diffuse pattern at the toes with a stardust pattern at the dorsum of the foot.</p>
Full article ">
Back to TopTop